Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by carduon Aug 03, 2010 12:56pm

520 Views

Post# 17317471

Ten month anniversary!

It was 10 months ago yesterday that the company reached an agreement with the FDA on the Phase 3 protocols. We are bleeding money every month that goes by. We have had no news PRs recently. We were promised regular updates on patient enrollment (as we haven't had any, I'll assume that they have not enrolled any patients).

I'd love to have a positive outlook but my patience, after over seven years, is wearing a wee bit thin. Give me some good news Mr. Thomson - if you have any.

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row